enVVeno Medical Corporation NVNO
8.67
(0.42)
(4.62%)
as of 25 Sep
- Market cap
- $6.3M
- P/E
- 0.0×
Follow NVNO
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
P/S ratio |
110.75 | 110.75 | 73.97 | 46.37 | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
P/Operating CF |
(19.75) | (19.75) | (9.56) | (5.34) | — | — | — | — | — | — |
P/B ratio |
0.00 | 0.00 | 6.78 | 8.75 | — | — | — | — | — | — |
Price to Tangible BV |
0.00 | 0.00 | 10.08 | 22.69 | — | — | — | — | — | — |
EV/Sales |
125.38 | 125.38 | 83.65 | 42.42 | — | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
EV/Operating CF |
(6.96) | (6.96) | (2.46) | (1.34) | — | — | — | — | — | — |
EV/FCF |
(7.17) | (7.17) | (2.45) | (1.27) | — | — | — | — | — | — |
Quick Ratio |
0.19 | 0.04 | 1.82 | 0.70 | 2.93 | 34.64 | 25.52 | 33.85 | 20.60 | 13.30 |
Current Ratio |
0.30 | 0.06 | 1.86 | 0.76 | 3.00 | 34.84 | 25.78 | 34.23 | 20.88 | 13.58 |
Net Debt/EBITDA |
(0.03) | (0.47) | 2.37 | 0.10 | 1.04 | 3.22 | 1.54 | 1.88 | 1.85 | 1.38 |
Debt/Assets |
10.54% | 93.63% | 0.00% | 16.54% | 2.41% | 2.97% | 3.37% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(0.04) | (0.19) | 0.00 | 0.57 | 0.04 | 0.03 | 0.04 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.39 | 0.21 | 0.06 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.92 | 0.51 | 0.39 | 0.77 | 0.79 | 0.72 | 0.63 | 0.80 | 0.77 | 0.80 |
Capex/Depreciation |
0.83 | 0.08 | 0.00 | (0.92) | (0.47) | (0.81) | (0.22) | (0.06) | (0.07) | (0.01) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 48.60% | 107.51% | 359.63% | (503.94%) | (240.92%) | (53.75%) | (52.98%) | (55.38%) | (49.39%) | (56.21%) | |
| (186.62%) | (412.80%) | (566.40%) | (218.07%) | (139.46%) | (48.44%) | (49.66%) | (52.09%) | (46.63%) | (52.26%) | |
ROIC |
0.00% | 0.00% | 0.00% | (1,914.23%) | 0.00% | (759.09%) | (1,433.53%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
412.10% | 302.67% | (1,220.17%) | 7,034.50% | (143.66%) | (30.56%) | (64.20%) | (51.25%) | (52.17%) | (72.78%) |
Average Days of Receivables |
88.15 | 30.44 | 62.59 | 0.00 | — | — | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 153.92% | 663.83% | 7,070.83% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
589.74% | 1,292.58% | 3,474.28% | 15,742.31% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.69 | 0.50 | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
192.16% | 208.10% | 1,030.28% | 3,019.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
(0.56) | (0.56) | 0.10 | (0.12) | — | — | — | — | — | — |
Graham Number |
0.00 | 6,317.32 | 0.00 | 0.00 | — | — | — | — | — | — |
Earnings Yield |
(35.50%) | (35.50%) | (122.99%) | (89.31%) | — | — | — | — | — | — |
Free Cash Flow Yield |
(15.79%) | (15.79%) | (46.22%) | (72.27%) | — | — | — | — | — | — |
Revenue per Share |
113.90 | 60.30 | 17.44 | 1.73 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(495.25) | (600.31) | (594.00) | (327.58) | (208.62) | (47.89) | (48.79) | (53.79) | (34.36) | (26.43) |
Capex per Share |
18.13 | 22.19 | (1.16) | (20.22) | (4.90) | (1.49) | (0.36) | (0.09) | (0.08) | (0.01) |
Free Cash Flow per Share |
(477.12) | (578.13) | (595.16) | (347.79) | (213.52) | (49.38) | (49.15) | (53.88) | (34.44) | (26.44) |
Cash per Share |
8.19 | 11.10 | 256.13 | 72.62 | 253.66 | 221.21 | 121.97 | 132.38 | 88.07 | 47.90 |
Shareholders Equity per Share |
(611.51) | (1,590.07) | 190.32 | 54.99 | 192.88 | 219.90 | 120.99 | 131.77 | 86.04 | 46.06 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(611.51) | (1,590.07) | 190.32 | 54.99 | 192.88 | 219.90 | 120.99 | 131.77 | 86.04 | 46.06 |
Free Cash Flow |
(3.29) | (4.05) | (6.37) | (6.26) | (7.86) | (12.22) | (15.73) | (18.89) | (16.87) | (15.57) |
Working Capital |
(0.93) | (2.75) | 1.31 | (0.45) | 6.38 | 53.46 | 37.91 | 45.55 | 41.64 | 26.70 |
Capital Expenditures |
0.13 | 0.16 | (0.01) | (0.36) | (0.18) | (0.37) | (0.11) | (0.03) | (0.04) | 0.00 |
Net Current Asset Value |
(5.61) | (13.17) | 1.31 | (1.02) | 6.13 | 51.75 | 36.50 | 44.49 | 40.94 | 26.39 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Capex to Sales |
(0.16) | (0.37) | 0.07 | 11.66 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
(474.65%) | (1,954.84%) | (8,763.50%) | (24,440.38%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
5.25 | 77.70 | 255.58 | 1.15 | 0.96 | 0.73 | 1.01 | 1.63 | 2.90 | 9.59 |
Cash ROIC |
86.69% | 47.07% | (133.60%) | (217.82%) | (48.40%) | (11.25%) | (20.39%) | (20.72%) | (19.95%) | (28.22%) |
Accounts Receivable Turnover |
6.99 | 3.75 | 5.55 | 0.00 | — | — | — | — | — | — |
Accounts Payable Turnover |
0.81 | 0.42 | 0.00 | 0.00 | 0.29 | 0.46 | 0.59 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
8.91 | 4.62 | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
244.14 | 1,262.06 | 0.00 | 0.00 | 1,321.60 | 451.31 | 845.41 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
40.95 | 79.05 | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.11 | 0.11 | 0.03 | — | — | — | — | — | — | — |
Average Payables |
1.00 | 1.00 | 1.26 | 1.15 | 1.31 | 0.98 | 0.89 | 1.12 | 1.38 | 1.73 |
Average Inventory |
0.09 | 0.09 | — | — | — | — | — | — | — | — |
Average Assets |
2.00 | 2.00 | 2.89 | 3.50 | 6.99 | 34.12 | 49.68 | 45.15 | 46.79 | 37.26 |
Average Common Equity |
(7.67) | (7.67) | (4.55) | 1.51 | 4.04 | 30.75 | 46.57 | 42.46 | 44.18 | 34.64 |
Columns are period end dates